Introduction
============

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood. It is defined as chronic inflammation of the synovial joints, with unknown etiology, which starts before the age of 16 years and persists for at least 6 weeks. There is a wealth of evidence to suggest that the pathogenesis is largely driven by T cells.^[@bib1]^ It has been shown that there is a strong bias in the overall T-helper (Th) 1 cytokine profile of synovial fluid (SF) T cells compared with peripheral blood T cells from patients with either oligoarticular or polyarticular JIA, and it is proposed that this polarization may be caused by selective recruitment by chemokine receptor expression.^[@bib2]^ CC chemokine receptor 5 (CCR5) is predominantly found on monocytes and T cells, particularly of the Th1 phenotype.^[@bib3]^ Its function is in the recruitment of these Th1 T cells to the synovium, where they accumulate and produce proinflammatory cytokines, such as interleukin-2 (IL2) and interferon-γ (which drives the inflammatory process and the consequent synovitis and joint destruction). CCR5 binds a number of proinflammatory chemokines, including CC chemokines, such as CCL3 (also known as macrophage inflammatory protein 1α), CCL4 (macrophage inflammatory protein β) and CCL5 (also known as regulated on activation, normal T-cell expressed and secreted).^[@bib4]^ These chemokines have been found at high levels in the SF of patients with adult rheumatoid arthritis (RA),^[@bib5]^ suggesting that CCR5+ T cells selectively accumulate in the SF in response to the presence of these chemokines. Furthermore, it has also been noted that the cell-surface CCR5 density determines the intensity of T-cell migration toward RA synoviocytes and also their stimulation by CCL5.^[@bib6]^ Thus, the level of CCR5 expression could favor the inflammatory effect of intra-articular T cells by facilitating their recruitment and increasing their response to chemokines. Therefore, the density of CCR5 on cells may be predictive of disease severity.

The *CCR5* gene on chromosome 3p21.3 contains a 32 base-pair insertion/deletion variant (*CCR5Δ32*), which leads to a frame shift and a nonfunctional receptor. Homozygosity for *CCR5Δ32* results in a complete lack of surface expression of CCR5, whereas heterozygotes express low densities of cell-surface CCR5 compared with individuals homozygous for the wild-type *CCR5* gene.^[@bib7]^ The polymorphism has been extensively studied in RA with conflicting evidence for a protective association of the *CCR5Δ32* polymorphism.^[@bib8],\ [@bib9],\ [@bib10],\ [@bib11],\ [@bib12]^ However, a large meta-analysis of five case--control association studies confirmed the protective association between *CCR5Δ32* and RA (odds ratio (OR) 0.65 95% confidence interval (95% CI): 0.55--0.77, *P*\<0.0001).^[@bib13]^ In JIA, again, the results are conflicting; one study reported that the *CCR5Δ32* variant was protectively associated with JIA;^[@bib14]^ another described no association;^[@bib15]^ and a third found that the *CCR5Δ32* variant was associated with JIA susceptibility.^[@bib16]^ The aim of this study was to investigate whether *CCR5Δ32* is associated with JIA in an UK population and to combine the results with those obtained in previous studies by meta-analysis.

Results
=======

Genotype counts conformed to Hardy--Weinberg expectations (*P*\>0.05) in the control cohort. After quality control, 987 JIA samples and 3121 control samples were available for analysis. We found that the *CCR5Δ32* variant was significantly associated with protection from developing JIA (*P*~trend~=0.006, OR 0.79 95% CI: 0.66--0.94) ([Table 1](#tbl1){ref-type="table"}).

Interestingly, the strongest protective effect was found in the rheumatoid factor-positive polyarthritis subtype (OR 0.41 95% CI: 0.18--0.93) ([Table 2](#tbl2){ref-type="table"}); however, there was no significant difference in allele frequencies across all the subtypes, suggesting that no subtype-specific associations exist.

To perform the meta-analysis, allele and genotype data from previous studies in JIA were collated ([Table 3](#tbl3){ref-type="table"}). Three previous studies were identified from literature searches: one from the United States,^[@bib14]^ the second, a study of Norwegian JIA cases and controls^[@bib15]^ and finally a study of Brazilian JIA cases and controls.^[@bib16]^ The US study was a family-based association analysis; hence for the meta-analysis, data collected from the parents and unaffected siblings were used as control data. Studies from the Unites States and Norway reported very similar control allele frequencies (10--11%). However, control allele frequencies in the Brazilian study by Scheibel *et al.* were very different (3.8%). This study was relatively small and reported association of the *CCR5Δ32* variant with JIA susceptibility. Inclusion of this study in the meta-analysis resulted in a *P*-value of 0.04 for the Breslow--Day test, suggesting significant heterogeneity between the studies. In view of the heterogeneity, the meta-analysis was, therefore, restricted to cohorts of Northern European descent and the results from the Brazilian cohort were not included in the calculation of the pooled OR. The pooled OR for the UK, US and Norwegian studies (Breslow--Day *P*=0.74) was 0.82 95% CI: 0.73--0.93, *P*=0.001. The combined analysis had a slightly more significant *P*-value and tighter CIs than that found for our UK JIA study alone ([Figure 1](#fig1){ref-type="fig"}).

Discussion
==========

The results from this investigation and the meta-analysis of previous studies suggest that the *CCR5Δ32* variant is associated with protection from developing JIA for individuals of Northern European descent. Our study was the largest to date to investigate this association and had \>80% power to detect a protective OR of ⩽0.75, similar to the effect size identified in the Prahalad meta-analysis for RA (OR=0.65).^[@bib13]^ The meta-analysis highlights the need for large sample sizes to detect variants with a modest effect.

The US family-based association study of the *CCR5Δ32* variant found no significant deviation of transmission of *CCR5Δ32* in the combined cohort of probands with JIA. However, stratification by age at onset found that *CCR5Δ32* was significantly undertransmitted to probands with early-onset JIA (\<6 years). In the UK cohort, there was no evidence for a stronger effect in cases with a young age at onset (*P*~trend~=0.1, OR 0.83 95% CI: 0.66--1.04); in fact, those with an older age at onset showed a slightly stronger effect (*P*~trend~=0.03, OR 0.77 95% CI: 0.60--0.97).

The same protective association has been found in RA but, as with JIA, there have been some conflicting results; however, a meta-analysis of five case--control association studies confirmed the protective association between *CCR5Δ32* and RA (OR 0.65 95% CI: 0.55--0.77, *P*\<0.0001). This is further evidence for shared susceptibility loci for RA and JIA, and adds to the evidence from other loci, which are associated with both diseases (and often other autoimmune diseases as well), such as *PTPN22*, *IL2/IL21* region, *IL2RA*, *AFF3*, *STAT4*, *TRAF1/C5* and *TNFAIP3*.^[@bib17],\ [@bib18],\ [@bib19]^ Indeed, the *CCR5Δ32* variant has previously been associated with protection from developing both type I diabetes and celiac disease,^[@bib20]^ suggesting a pan-autoimmune disease role.

The influence of *CCR5Δ32* on the clinical course of RA has also been investigated, but again the evidence is often conflicting, with the most recent study finding that carriers of the deletion were protected from joint erosion, had less extra-articular manifestations and had lower cumulative C-reactive protein levels.^[@bib21]^ However, a number of other studies have found no evidence for an association with disease severity or outcome.^[@bib10],\ [@bib22],\ [@bib23]^ These discrepancies may arise as a result of differences in statistical power and methodologies used but, given the fact that CCR5 expression levels may be associated with severity, it would be interesting to investigate whether *CCR5Δ32* has any effect on outcome in JIA. Data from the CAPS (Childhood Arthritis Prospective Study), a prospective inception cohort study of JIA cases, will be invaluable in exploring this hypothesis, but are insufficiently powered at present to undertake these investigations.

The observation that there are six JIA cases that are homozygous for *CCR5Δ32* suggests that there may be some redundancy in the chemokine system and other receptors and ligands may have a role in the development of JIA. A previous study that found high expression of two chemokine receptors, CCR5 and CXCR3 on SF on T cells from 20 JIA patients compared with peripheral blood T cells also found some evidence of redundancy.^[@bib2]^ In that study, one of the JIA patients was homozygous for *CCR5Δ32* but was, perhaps surprisingly, of the more severe extended oligoarthritis subtype. This individual had high levels of CXCR3 on SF T cells and had a high interferon-γ:IL4 ratio in the cytokine stimulation assay. In most cases, SF T cells were double positive for CCR5 and CXCR3, but T cells can express one or the other. The different coexpression also suggests that the levels of these two receptors are regulated by different factors.

It has been proposed that CCR5 is important in the recruitment of Th1 T cells to the joint but also, interestingly, a number of studies have linked CCR5 to the IL2 pathway. For example, IL2 upregulates CCR5 expression *in vivo* and *in vitro*^[@bib24],\ [@bib25],\ [@bib26]^ and rapamycin, a drug that disrupts IL2 receptor signaling, reduces CCR5 surface expression on T cells.^[@bib27]^ A recent study found that *CCR5Δ32*/*Δ32* donors of peripheral blood mononuclear cells stimulated by antiCD3/CD28 showed significantly less IL2 production than did noncarriers of the *CCR5Δ32* mutation. They showed that CCR5 influenced IL2 transcript levels and also that CCR5 influenced the expression of IL2RA/CD25 on CD4+ T cells both *in vitro* and *in vivo*. There was evidence that these effects are mediated through the nuclear factor of activated T cell signaling pathway. CCR5 expression was also shown to promote T-cell proliferation after T-cell activation.^[@bib28]^ This is fascinating in that the *IL2* gene region^[@bib19],\ [@bib29]^ and *IL2RA* genes^[@bib30]^ are also associated with JIA. Interestingly, in all three cases, the SNP in the gene/region is associated with protection from JIA.

In conclusion, we have presented evidence for a protective association of the *CCR5Δ32* variant in an UK JIA case--control cohort, which is strengthened by combining data obtained from two previous studies in populations of Northern European descent by meta-analysis. Further investigation into how this gene contributes to JIA pathogenesis is now required.

Materials and methods
=====================

Subjects
--------

DNA was available for 1054 UK Caucasian JIA patients (332 males and 715 females) from three sources: BSPAR (The British Society for Paediatric and Adolescent Rheumatology) National Repository of JIA (*n*=654); a group of UK Caucasian patients with long-standing JIA (*n*=201), described previously;^[@bib31]^ and a third cohort collected as part of the CAPS, a prospective inception cohort study of JIA cases from five centers across the United Kingdom (*n*=199).^[@bib32]^ JIA cases were classified according to the ILAR criteria^[@bib33]^ (Supplementary Table 1). Healthy Caucasian control DNA samples (*n*=3129) were available from five centers in the United Kingdom as described previously:^[@bib34]^ Manchester, Sheffield, Leeds, Aberdeen and Oxford (total control sample size after quality control=3121). All individuals were recruited with ethical approval and provided informed consent (North-west Multi-Centre Research Ethics Committee (MREC 99/8/84) and the University of Manchester Committee on the Ethics of Research on Human Beings).

Genotyping
----------

The *CCR5Δ32* variant (rs333) was genotyped using the Sequenom iPlex MassARRAY platform according to the manufacturer\'s instructions (Sequenom, San Diego, CA, USA; <http://www.sequenom.com/>). A 90% sample quality control rate and a 90% genotyping success rate were imposed on the analysis.

Statistical analysis
--------------------

Power calculations were performed using QUANTO to calculate the prior probability of detecting association in the current sample size at the allele frequency and effect sizes were reported previously in other autoimmune diseases for this variant.^[@bib14]^ Calculations assumed a log-additive model, an *α* value of 0.05 and an effect size of 0.75. Genotype and allele frequencies were compared between cases with JIA and controls using the Cochrane--Armitage trend test implemented in PLINK (<http://pngu.mgh.harvard.edu/purcell/plink/>),^[@bib35]^ and allelic ORs and their 95% CIs were calculated. JIA is a phenotypically heterogeneous disease and can be classified into more clinically homogeneous diseases using the ILAR classification criteria.^[@bib36]^ However, comparing each of the ILAR subtypes separately against controls would result in a large number of hypothesis tests. Therefore, we also examined whether there was evidence of a difference in allele frequencies between the seven ILAR subtypes. Differences between subtypes were assessed using χ^2^-tests on the 7 × 2 tables.

Published case--control association studies of *CCR5Δ32* with JIA were identified using a PUBMED search. Genotype and allele frequencies were obtained from the published studies. A test for heterogeneity between cohorts was carried out using the Breslow--Day test, and the Cochran--Mantel--Haenszel test was used to perform a meta-analysis of the three cohorts.
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###### 

Click here for additional data file.

![Meta-analysis of three studies of the *CCR5Δ32* variant. Meta-analysis of UK, US and Norwegian JIA cohorts for the CCR5 gene. Forest plot displaying odds ratios and 95% confidence intervals for each of the studies and the weighting for each study according to sample size. The combined OR from the three studies is displayed as a diamond with the peaks denoting the upper and lower limits of the confidence intervals. Values below 1 depict a negative (protective) association. The Breslow-Day test was performed to test for heterogeneity between the two studies, with a significant *P*-value suggesting heterogeneity between studies. The combined *P*-value is displayed below the heterogeneity *P*-value.](gene201025f1){#fig1}

###### Association analysis of the *CCR5Δ32* variant in UK JIA cases and controls

  *Variant*            *CHR*   *Position*   *Minor allele*   *Major allele*   *MAF cases*   *MAF controls*   *Case 11* (%)   *Case 12* (%)   *Case 22* (%)   *Control 11* (%)   *Control 12* (%)   *Control 22* (%)   P~*trend*~    *OR (95*% *CI)*
  ------------------- ------- ------------ ---------------- ---------------- ------------- ---------------- --------------- --------------- --------------- ------------------ ------------------ ------------------ ------------ -------------------
  *CCR5Δ32* (rs333)      3      46414947          T                G             0.09            0.11           6 (0.6)       169 (17.2)      808 (82.2)         35 (1.1)          642 (20.6)        2444 (78.3)        0.006      0.79 (0.66--0.94)

Abbreviations: CHR, chromosome; CI, confidence interval; JIA, juvenile idiopathic arthritis; MAF, minor allele frequency; OR, odds ratio.

###### JIA ILAR subtype stratification analysis

  *JIA ILAR subtype*             *MAF cases*   *MAF controls*   P~*trend*~   *OR*    *95*% *CI*
  ------------------------------ ------------- ---------------- ------------ ------ ------------
  Systemic onset JIA             0.12          0.11             0.94         1.01    0.71--1.45
  Persistent oligoarthritis      0.09          0.11             0.1          0.78    0.57--1.06
  Extended oligoarthritis        0.09          0.11             0.2          0.76    0.49--1.16
  RF-negative polyarthritis      0.11          0.11             0.63         0.92    0.66--1.29
  RF-positive polyarthritis      0.05          0.11             0.03         0.41    0.18--0.93
  Enthesitis-related arthritis   0.11          0.11             0.79         0.93    0.52--1.66
  Psoriatic arthritis            0.06          0.11             0.06         0.53    0.27--1.04

Abbreviations: CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; RF, rheumatoid factor.

###### Allele frequencies in patients with JIA and healthy controls for the *CCR5Δ32* variant

  *Author (references)*             *Country*     *Subjects*   *JIA*         *Subjects*   *Controls*                        *OR (95*% *CI)*                
  ------------------------------ ---------------- ------------ ------------- ------------ --------------------------------- ----------------- ------------ -------------------
  Prahalad *et al.*^[@bib14]^     United States   833          1519 (91.2)   147 (8.8)    1708[a](#t3-fn2){ref-type="fn"}   3076 (90.0)       340 (10.0)   0.88 (0.72--1.07)
  Lindner *et al.*^[@bib15]^          Norway      515          931 (90.4)    99 (9.7)     645                               1142 (88.5)       148 (11.5)   0.82 (0.63--1.08)
  Hinks *et al.*^[@bib17]^        United Kingdom  983          1785 (90.8)   181 (9.2)    3121                              5530 (88.6)       712 (11.4)   0.79 (0.66--0.93)
  Schiebel *et al.*^[@bib16]b^        Brazil      101          183 (90.6)    19 (9.4)     104                               200 (96.2)        8 (3.8)      2.6 (1.1--6.07)

Abbreviations: CI, confidence interval; JIA, juvenile idiopathic arthritis; OR, odds ratio.

Controls are parents and unaffected siblings of the probands.

Not included in the meta-analysis.

[^1]: Members of CAPS, the UKRAG and the BSAR are listed in the Appendix.
